Stock events for ACADIA Pharmaceuticals, Inc. (ACAD)
In the past six months, ACADIA Pharmaceuticals' stock has trended down, but over the last year, the stock has shown an increase. Key events impacting the stock price include a strong Q4 2025 earnings report, a negative CHMP opinion for DAYBUE in Europe, and a Phase 3 trial failure for ACP-101.
Demand Seasonality affecting ACADIA Pharmaceuticals, Inc.’s stock price
There is evidence of demand seasonality for ACADIA Pharmaceuticals' products. DAYBUE sales have experienced typical seasonality at the beginning of the year, with a potential dip in the first quarter.
Overview of ACADIA Pharmaceuticals, Inc.’s business
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system disorders and rare diseases. Its major commercial products include NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome. The company also has a pipeline of product candidates, including ACP-101 for Prader-Willi syndrome, Remlifanserin for Alzheimer's disease psychosis and Lewy body dementia psychosis, and Pimavanserin for major depressive disorder and schizophrenia.
ACAD’s Geographic footprint
ACADIA Pharmaceuticals is headquartered in San Diego, California, U.S. The company is pursuing international expansion with regulatory filings in Canada, Israel, and the European Union. It has also initiated managed access programs in the European Union and maintains operational presences in Denmark, Switzerland, and the UK.
ACAD Corporate Image Assessment
ACADIA Pharmaceuticals has a reputation as a leader in the neuroscience space, focusing on unmet medical needs in central nervous system disorders and rare diseases. The negative CHMP opinion for DAYBUE in Europe and the Phase 3 trial failure for ACP-101 could impact the company's reputation. However, the company's strong commercial performance of NUPLAZID and DAYBUE highlights its strategic focus and ability to address critical medical needs.
Ownership
ACADIA Pharmaceuticals' ownership is heavily influenced by institutional investors, holding a significant percentage of the stock. Major institutional shareholders include Baker Bros. Advisors Lp, BlackRock, Inc., and Vanguard Group Inc. Felix Baker is a significant insider shareholder, and insiders collectively own a notable portion of the company's shares.
